01:38 , Feb 15, 2019 |  BC Week In Review  |  Company News

3-V raises $18M, partners NASH program with Ascletis

3-V Biosciences Inc. (Menlo Park, Calif.) raised a $18 million series E round on Feb. 13 and granted lead investor Ascletis Pharma Inc. (HKEX:1672) exclusive rights in Greater China to TVB-2640, an inhibitor of fatty...
20:18 , Feb 13, 2019 |  BC Extra  |  Financial News

3-V raises $18M, partners NASH program with Ascletis

3-V Biosciences Inc. (Menlo Park, Calif.) raised a $18 million series E round and granted lead investor Ascletis Pharma Inc. (HKEX:1672) exclusive rights in Greater China to TVB-2640, an inhibitor of fatty acid synthase (FASN;...
18:19 , Jun 29, 2018 |  BC Week In Review  |  Company News

Ascletis, CR Pharmaceutical partner to distribute HCV drug in Beijing

Ascletis Pharma Inc. (Hangzhou, China) partnered with the CR Pharmaceutical Commercial Group Co. Ltd. subsidiary of China Resources Pharmaceutical Group Ltd. (Beijing, China) to develop distribution networks and end-user services in Beijing for the launch...
16:11 , May 30, 2018 |  BC Extra  |  Company News

Gilead's Epclusa approved in China for HCV

Gilead Sciences Inc. (NASDAQ:GILD) said China's State Drug Administration (formerly China FDA) approved Epclusa sofosbuvir/velpatasvir to treat adults with chronic HCV genotypes 1-6. The agency also approved Epclusa plus ribavirin to treat adults with HCV...
01:18 , May 12, 2018 |  BioCentury  |  Finance

HKEX opportunity knocking

The rapid growth of biotech in the greater China region is something Jefferies does not intend to miss. With the opening of a new biotech chapter on the Hong Kong Exchanges and Clearing Ltd. on...
22:19 , Mar 16, 2018 |  BioCentury  |  Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for...
19:08 , Jan 19, 2018 |  BioCentury  |  Finance

Incubating in China

C-Bridge Capital is one of the newer venture funds in Chinese healthcare seeking to bring mature platforms or programs from the Western market into China. Compared with most other Chinese VCs, however, C-Bridge is investing...
01:27 , Dec 2, 2017 |  BioCentury  |  Strategy

Opening the gates in China

A flurry of approvals of HCV drugs in China this year illustrates how the country’s regulatory reforms have leveled the playing field for multinational drug sponsors, who had been disadvantaged compared with domestic companies. As...
21:54 , Sep 25, 2017 |  BC Extra  |  Company News

Gilead's Sovaldi gets Chinese approval

Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen in patients ages 12 and older. Gilead said the nucleotide analog HCV...
18:01 , Sep 1, 2017 |  BC Week In Review  |  Company News

Medivir grants Ascletis rights to preclinical HCV candidate

Medivir AB (SSE:MVIR B) granted Ascletis BioScience Co. Ltd. (Hangzhou, China) exclusive development and commercialization rights in Greater China to preclinical HCV candidate MIV-802 . Medivir received an upfront payment and is eligible for milestones...